A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | MicrobiomeTrials
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-05-27Est. Completion: 2027-07-31
Enrollment target: 304 participants
Locations
South Coast Retina Center - RCA, Long Beach, California, United States
California Eye Specialists Medical Group, Inc, Pasadena, California, United States
Retina Consultants of San Diego, Poway, California, United States
Retinal Consultants Medical Group, Inc - Sacramento - Parkcenter Drive (RCA), Sacramento, California, United States
Retina Group of Florida, Fort Lauderdale, Florida, United States
Medeye Associates - Research, Miami, Florida, United States
Advanced Research, LLC, Pensacola, Florida, United States
Retina Associates, Elmhurst, Illinois, United States
Retina Consultants of Minnesota, Edina, Minnesota, United States
Mississippi Retina Assoc, Madison, Mississippi, United States
Charleston Neuroscience Institute, Charleston, South Carolina, United States
Retina Consultants of South Carolina, Charleston Neuroscience Institute- Ladson (RCA), Ladson, South Carolina, United States
Palmetto Retina Center, Florence (RCA), West Columbia, South Carolina, United States
Texas Retina Associates (TRA) - Arlington, Arlington, Texas, United States
Other microbiome trials you might be interested in